{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermediate+dose&page=11",
    "query": {
      "intervention": "Intermediate dose",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 2633,
    "total_pages": 264,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermediate+dose&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermediate+dose&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T16:24:41.463Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02767089",
      "title": "The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Adults"
      ],
      "interventions": [
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 37,
      "start_date": "2005-10",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2016-05-10",
      "last_synced_at": "2026-10-24T16:24:41.463Z",
      "location_count": 1,
      "location_summary": "Kalamazoo, Michigan",
      "locations": [
        {
          "city": "Kalamazoo",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02767089"
    },
    {
      "nct_id": "NCT02705313",
      "title": "EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "177Lu-DOTA0-Tyr3-Octreotate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advanced Accelerator Applications",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-04-09",
      "last_synced_at": "2026-10-24T16:24:41.463Z",
      "location_count": 41,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 33 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02705313"
    },
    {
      "nct_id": "NCT05610189",
      "title": "Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Tavapadon",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cerevel Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "45 Years to 80 Years"
      },
      "enrollment_count": 25,
      "start_date": "2022-12-15",
      "completion_date": "2023-12-17",
      "has_results": false,
      "last_update_posted_date": "2024-02-08",
      "last_synced_at": "2026-10-24T16:24:41.463Z",
      "location_count": 6,
      "location_summary": "Los Alamitos, California • Hollywood, Florida • Orlando, Florida + 3 more",
      "locations": [
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05610189"
    },
    {
      "nct_id": "NCT03113825",
      "title": "Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Invasive Malignant Neoplasm of Female Breast",
        "Carcinoma Breast",
        "Breast Cancer Female",
        "Carcinoma, Ductal, Breast",
        "Stage II Breast Cancer",
        "Stage I Breast Cancer",
        "Stage III Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Investigational Imaging device",
          "type": "DEVICE"
        },
        {
          "name": "AVB-620",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Avelas Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 92,
      "start_date": "2017-07-05",
      "completion_date": "2020-11-18",
      "has_results": false,
      "last_update_posted_date": "2021-06-11",
      "last_synced_at": "2026-10-24T16:24:41.463Z",
      "location_count": 13,
      "location_summary": "San Diego, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Barrington",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03113825"
    },
    {
      "nct_id": "NCT04850274",
      "title": "Using Re-inforcement Learning to Automatically Adapt a Remote Therapy Intervention (RTI) for Reducing Adolescent Violence Involvement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Violence",
        "Substance Use",
        "Criminal Behavior",
        "Violence in Adolescence"
      ],
      "interventions": [
        {
          "name": "Remote Therapy Intervention (RTI)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Artificial Intelligence Remote Therapy Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "14 Years to 24 Years"
      },
      "enrollment_count": 584,
      "start_date": "2021-05-19",
      "completion_date": "2026-02-13",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-10-24T16:24:41.463Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Detroit, Michigan • Flint, Michigan + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Flint",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04850274"
    },
    {
      "nct_id": "NCT00549913",
      "title": "Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Degenerative Disc Disease",
        "Spondylolisthesis",
        "Spinal Stenosis"
      ],
      "interventions": [
        {
          "name": "NeoFuse",
          "type": "BIOLOGICAL"
        },
        {
          "name": "posterolateral spinal fusion with instrumentation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Mesoblast, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2007-10",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2020-06-29",
      "last_synced_at": "2026-10-24T16:24:41.463Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00549913"
    },
    {
      "nct_id": "NCT06242535",
      "title": "Pilot Study of GLY-LOW Supplementation in Postmenopausal Women With Obesity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Insulin Resistance",
        "Obesity",
        "Cardiovascular Diseases",
        "Cognitive Impairment",
        "Physical Disability",
        "Depression",
        "Inflammation",
        "Hormone Deficiency",
        "Physical Inactivity",
        "Hyperlipidemias",
        "Hypertension",
        "Overeating"
      ],
      "interventions": [
        {
          "name": "GLY-LOW",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Hoskinson Health and Wellness Clinic",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "56 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "56 Years and older · Female only"
      },
      "enrollment_count": 13,
      "start_date": "2023-07-27",
      "completion_date": "2024-05-31",
      "has_results": false,
      "last_update_posted_date": "2025-06-10",
      "last_synced_at": "2026-10-24T16:24:41.463Z",
      "location_count": 1,
      "location_summary": "Gillette, Wyoming",
      "locations": [
        {
          "city": "Gillette",
          "state": "Wyoming"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06242535"
    },
    {
      "nct_id": "NCT02078674",
      "title": "A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza (Pandemic)"
      ],
      "interventions": [
        {
          "name": "Monovalent Avian Influenza VLP (H7N9)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Matrix-M1™ adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 610,
      "start_date": "2014-03",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2016-09-23",
      "last_synced_at": "2026-10-24T16:24:41.463Z",
      "location_count": 5,
      "location_summary": "Walnut Creek, California • Miami, Florida • Meridian, Idaho + 2 more",
      "locations": [
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        },
        {
          "city": "Endwell",
          "state": "New York"
        },
        {
          "city": "Mt. Pleasant",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02078674"
    },
    {
      "nct_id": "NCT05255276",
      "title": "PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Adults"
      ],
      "interventions": [
        {
          "name": "Sitravatinib 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Sitravatinib 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirati Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2022-02-02",
      "completion_date": "2023-02-10",
      "has_results": false,
      "last_update_posted_date": "2024-05-08",
      "last_synced_at": "2026-10-24T16:24:41.463Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05255276"
    },
    {
      "nct_id": "NCT01263197",
      "title": "A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "LY2216684",
          "type": "DRUG"
        },
        {
          "name": "albuterol",
          "type": "DRUG"
        },
        {
          "name": "propranolol",
          "type": "DRUG"
        },
        {
          "name": "placebo for LY2216684",
          "type": "DRUG"
        },
        {
          "name": "placebo for albuterol",
          "type": "DRUG"
        },
        {
          "name": "placebo for propranolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2010-12",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2019-01-29",
      "last_synced_at": "2026-10-24T16:24:41.463Z",
      "location_count": 1,
      "location_summary": "Evansville, Indiana",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01263197"
    }
  ]
}